Daiichi Sankyo launches phase 1 trial of DS-1205 in EGFR-mutated NSCLC

For patients with metastatic EGFR-mutated NSCLC, targeted EGFR TKI therapies such as gefitinib, erlotinib, afatinib or osimertinib represent the first-line treatment of choice. However, patients eventually develop resistance